MiRNA-190 suppresses the tumor microenvironment by targeting a set of angiogenic genes including RAS2, TCF4, HGF, Smad2, Smad4, IGF1, Jak2, and VEGF in vivo and in vitro (Hao et al., 2014). The gene discussed is VEGFA; the disease is neoplasm.